首页 | 官方网站   微博 | 高级检索  
     

大鼠重复ig给予N-[(3-烯丙基-2-羟基)苯亚甲基-2-(4-苄基-高哌嗪-1-基)乙酰肼富马酸盐的药动学研究
引用本文:刘淑洁,于敏,王宇,黄舒佳,张颖丽,闻镍,淡墨,耿兴超,刘丽.大鼠重复ig给予N-[(3-烯丙基-2-羟基)苯亚甲基-2-(4-苄基-高哌嗪-1-基)乙酰肼富马酸盐的药动学研究[J].现代药物与临床,2022,45(9):1830-1835.
作者姓名:刘淑洁  于敏  王宇  黄舒佳  张颖丽  闻镍  淡墨  耿兴超  刘丽
作者单位:中国食品药品检定研究院, 国家药物安全评价监测中心, 药物非临床安全评价研究北京市重点实验室, 北京 100176;国家药品监督管理局 药品审评中心, 北京 100022
基金项目:“十三五”国家“重大新药创制”科技重大专项(2018ZX09201017-001)
摘    要:目的 采用高效液相色谱-串联质谱法(HPLC-MS/MS)测定SD大鼠血浆中N-[(3-烯丙基-2-羟基)苯亚甲基]-2-(4-苄基-高哌嗪-1-基)乙酰肼富马酸盐(SM-1),并计算大鼠重复ig给药的药动学参数,评价SM-1的药动学特征。方法 将60只健康SPF级SD大鼠随机分为阴性对照组、溶媒对照组和SM-1低、中、高剂量组,每组16只动物(阴性对照组和溶媒对照组为6只动物),雌雄各半。每天ig给药1次,各组分别给予水、溶媒或SM-1 50、100、200 mg·kg-1,给药体积10 mL·kg-1,连续给药4周,于首次给药和末次给药阶段进行药动学采血测定。采用经验证的HPLC-MS/MS法测定SD大鼠血浆中SM-1浓度。使用Phoenix WinNonlin 7.0软件进行血药浓度-时间数据分析与药动学参数计算。结果 SD大鼠ig给予SM-1后,在50~200 mg·kg-1剂量,SD大鼠体内的平均峰浓度(Cmax)及药时曲线下面积(AUC0~t)随剂量的增加而增加,各剂量组动物平均Cmax及AUC0~t比值与剂量比相近。连续给药后,低、中、高剂量组均未出现明显的蓄积。雌性大鼠SM-1的暴露高于雄性大鼠。结论 连续给药28 d后,SM-1在大鼠体内未出现明显的蓄积,雌性大鼠SM-1的暴露高于雄性大鼠。

关 键 词:N-[(3-烯丙基-2-羟基)苯亚甲基]-2-(4-苄基-高哌嗪-1-基)乙酰肼富马酸盐(SM-1)  高效液相色谱-串联质谱法  药动学  蓄积  体内暴露
收稿时间:2022/2/12 0:00:00

Pharmacokinetics of repeated administration of N-[(3-allyl-2-hydroxy) phenylmethylene]-2-(4-benzyl-piperazine-1-yl) acetylhydrazine fumarate in SD rats
LIU Shujie,YU Min,WANG Yu,HUANG Shuji,ZHANG Yingli,WEN Nie,DAN Mo,GENG Xingchao,LIU Li.Pharmacokinetics of repeated administration of N-[(3-allyl-2-hydroxy) phenylmethylene]-2-(4-benzyl-piperazine-1-yl) acetylhydrazine fumarate in SD rats[J].Drugs & Clinic,2022,45(9):1830-1835.
Authors:LIU Shujie  YU Min  WANG Yu  HUANG Shuji  ZHANG Yingli  WEN Nie  DAN Mo  GENG Xingchao  LIU Li
Affiliation:Beijing Key Laboratory of Non-Clinical Drug Safety Evaluation Research, National Center for Safety Evaluation of Drugs, National Institute of Food and Drug Control, Beijing 100176, China;Centre for Drug Evaluation, National Medical Products Administration, Beijing 100022, China
Abstract:Objective A simple and sensitive high performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method was used in the determination of N-(3-allyl-2-hydroxy) phenylmethylene] -2- (4-benzyl-piperazine-1-yl) acetylhydrazine fumarate (SM-1) in SD rat plasma. The pharmacokinetics parameters were calculated to evaluate the pharmacokinetic characteristics of repeated administration of SM-1. Methods 60 healthy SPF SD rats were randomly divided into negative control group, solvent control group, SM-1 low, medium and high dose groups with 16 rats in each group (six rats in negative control group and vehicle control group), half male and half female. Each group was given water, solvent or SM-1 50, 100, 200 mg·kg-1 by gavage administration in volume of 10 mL·kg-1, once a day for four weeks. Blood samples were collected at the first and last administration stages. HPLC-MS/MS method was used in determination of SM-1 in SD rat plasma. Phoenix WinNonlin 7.0 software was used to analyze the pharmacokinetic characteristic. Results The average Cmax and AUC0-t of SM-1 in SD rats increased with the increase of dose in the range of 50-200 mg·kg-1, and the average Cmax and AUC0-t ratio of each dose were similar to the dose ratio. After continuous administration, there was no obvious accumulation in low, medium or high dose groups. The exposure of SM-1 in female rats was higher than that in male rats. Conclusion After continuous administration for 28 d, there was no obvious accumulation in low, medium or high dose groups. The exposure of SM-1 in female rats was higher than that in male rats.
Keywords:N-[(3-allyl-2-hydroxy) phenylmethylene]-2-(4-benzyl-piperazine-1-yl) acetylhydrazine fumarate (SM-1)  high performance liquid chromatography tandem mass spectrometry  pharmacokinetics  accumulation  exposure in vivo
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号